EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer

P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)

LF Valle, EJ Lehrer, D Markovic, D Elashoff… - European urology, 2021 - Elsevier
Context Management of locally recurrent prostate cancer after definitive radiotherapy
remains controversial due to the perceived high rates of severe genitourinary (GU) and …

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an …

A Pollack, TG Karrison, AG Balogh, LG Gomella… - The Lancet, 2022 - thelancet.com
Background In men with a detectable prostate-specific antigen (PSA) level after
prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in …

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

CC Parker, NW Clarke, AD Cook, HG Kynaston… - The Lancet, 2020 - thelancet.com
Background The optimal timing of radiotherapy after radical prostatectomy for prostate
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …

[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …

S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi… - European urology, 2023 - Elsevier
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019

S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell… - European urology, 2020 - Elsevier
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical …

P Sargos, S Chabaud, I Latorzeff, N Magné… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre …

AB Jani, E Schreibmann, S Goyal, R Halkar… - The Lancet, 2021 - thelancet.com
Background Molecular imaging is increasingly used to guide treatment decisions and
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

ND Shore, JW Moul, KJ Pienta, J Czernin… - Prostate Cancer and …, 2024 - nature.com
Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …

Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death

D Tilki, MH Chen, J Wu, H Huland… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Adjuvant compared with early salvage radiation therapy (sRT) following radical
prostatectomy (RP) has not been shown to reduce progression-free survival in randomized …